Evidence map›Paper›PMID 38610928›Full record

ArticleCancers2024

Impact of

Eglė Balčiūnienė, Arturas Inčiūra, Elona Juozaitytė, Rasa Ugenskienė

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eglė BalčiūnienėInstitute of Oncology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Arturas InčiūraInstitute of Oncology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Elona JuozaitytėInstitute of Oncology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.ORCID 0000-0001-6695-7786
Rasa UgenskienėInstitute of Oncology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

Lithuanian University of Health Sciences Company code: 302536989, VAT code: LT1000055793
6 · The paper itself

Abstract

Metastasis is a key determinant of cancer progression, influenced significantly by genetic mechanisms. RRP1B, primarily a nucleolar protein, emerges as a suppressor of metastasis, forming alliances with various cellular components and modulating gene expression. This study investigates the involvement of the ribosomal RNA processing 1 homolog B (

Indexed as

cervical cancergenotypehaplotypemetastasispolymorphismsRRP1Bsurvival

Identifiers

PMID38610928
PMCPMC11011178
OpenAlexW4393082068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.